Thank you, Mr. Chair. I appreciate it.
Thank you to all the witnesses. I really appreciate your expertise and your dedication to the area. I do appreciate that.
As our chair indicated, we're eager to ask questions. I have so many that I just don't know where to start.
I'll start with Dr. Cohen Tervaert.
You talked a little bit about RCTs, randomized controlled trials, and about how we don't have any along those lines. Because we're looking at this from a registry point of view, I'm wondering how you see collecting the data—assuming we're collecting that data—would be of value to produce that RCT research.